川芎嗪和尼群地平配伍治疗慢性阻塞性肺病的机制探讨

作者	单位
林春龙	湖南省岳阳市第一人民医院呼吸内科
张珍祥	同济医科大学附属同济医院呼吸内科
徐永健	同济医科大学附属同济医院呼吸内科

摘要点击次数: 1431

全文下载次数: 1140

中文摘要:

目的 :探讨川芎嗪与尼群地平降低慢性阻塞性肺病 (慢阻肺 )患者肺循环阻力的治疗机制。方法 :分别应用川芎嗪、尼群地平及川芎嗪与尼群地平配伍 3种方法治疗慢阻肺患者各 10例 ,测定用药前后血液流变学参数及血浆内皮素 1(ET1)、血栓素A2 (TXA2 )、血小板 -P -选择素 (CD62P)等水平。结果 :川芎嗪与尼群地平配伍能降低血浆ET1、TXA2 、CD62P水平 ,同时下调血液流变学各指标。结论 :川芎嗪与尼群地平配伍能增强各自单独用药的效果 ,其降低肺循环阻力的作用与降低血浆中缩血管因子及改变血液流变学有关。

英文摘要:

To study the therapeutic mechanism of combination therapy of ligustrazine and nitrendipine in treating patients with chronic obstructive pulmonary disease (COPD). Methods: Thirty COPD patients divided in to 3 groups (10 in each) were treated with ligustrazine, nitrendipine and ligustrazine plus nitrendipine respectively, and the changes of hemorrheologic parameters, plasma endothelin (ET-1), thromboxane A 2 (TXA 2) and platelet-P-selectin (CD62P) before and after treatment were observed. Results: The combination therapy of ligustrazine and nitrendipine could lower the levels of plasma ET-1, TXA 2, CD62P and the hemorrheologic parameters. Conclusion: Combination of ligustrazine and nitrendipine showed a therapeutic effect better than that of the two drugs used separately. Its effect in lowering pulmonary circulation resistance is related with the lowering of plasma vaso-contrictive factor and the changing of hemorrheologic properties. The integrated traditional Chinese and western medical therapy is valuable in treating COPD.

关闭